HB Human BioScience S.A.S.
| ISIN | 🆔 |
|---|---|
| Industry | Pharmaceutical |
| Founded 📆 | 2011 |
| Founders 👔 | Alejandro Pérez Oscar Otálora |
| Headquarters 🏙️ | Bogotá, Cundinamarca, Colombia. |
Area served 🗺️ | South America |
| Products 📟 | See #Products |
| Members | |
Number of employees | 51 (2018) |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
HB Human BioScience is a Colombian pharmaceutical company. It is headquartered in Bogotá, Colombia. HB Human BioScience’s primary area of business is human pharmaceuticals, focused in oncology and rare diseases. Since its founding the company's motto has been "Innovation and Technology"..[1]. Its activities include research, development, production, import, export, manufacturing, distribution and marketing of various medications and medical devices in Colombia and nearby countries for critical care therapies.
History[edit]
Hb Human BioScience is a simplified stock company, founded in 2011 with a registered address in the city of Bogotá, Colombia. The company is mainly engaged in wholesale trade of pharmaceutical and medicinal products[2]. The company began its operations in Colombia by importing and distributing named patient orphan drugs. The first drug to receive a Marketing Authorization was Thymogam, a horse derived Anti-thymocyte globuline developed and produced by Bharat Serums And Vaccines Limited of India[3].
In August 2013, the company opened its first two subsidiaries in Peru[4] and Ecuador, beginning its international expansion. Currently, HB Human BioScience has offices in Colombia, Peru[5], Ecuador and India.
Over the years, HB Human BioScience have teamed up with many global companies such as Galen Limited (UK), Helm AG (Germany), Strides Arcolab (India), AET (Germany), Almac Group (UK), Bharat Serums and Vaccines (India), Orion (Finland), PharmaCept (Germany), and Qilu (China) to in license products. In addition to its licensing model, the company also count with an infrastructure for named patient sales[6].
HB Human BioScience was involved in a series of controversial legal actions related to the implementation of drugs price control policies by the Colombian government in 2013 through the National Committee on Drug Prices, as the regulation effectively reduced the price of a drug developed by Bharat Biotech International and distributed by the company[7][8]. The Embassy of India in Colombia, as well as the Embassy of the United States of America, spoke on the matter through letters addressed to the Ministry of Health and Social Protection, in order to mediate the process[9].
In 2014, a series of circulars issued by the Ministry of Health generated the price control of about 814 medicines from different laboratories, including at least one product of HB Human BioScience: HB Oncofeme, a commercial form of Exemestane, a drug indicated for the treatment of Breast cancer. These measures were the initiative of the then Minister of Health and Social Protection Alejandro Gaviria[10]. By 2017, the price of at least four aditional products distributed by the company were regulated by subsequent policies of price control implemented by the Ministry of Health, through the National Committee on Drug and Medical Device Prices[11].
In 2016, according to its Executive Director, the company achieved a growth of 25 percent in sales by launching new products to the market[12].
In August 2018, the Tokyo-headquartered oncology specialty firm Solasia Pharma K.K., announced that Solasia and HB Human BioScience have entered into an exclusive license agreement pertaining the development and commercialization of SP-02 (also known as darinaparsin) in Latin America[13], which Solasia holds the global rights to develop and commercialize and is currently conducting clinical development in Asia. The licensed territory to HB Human BioScience includes Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala. Solasia obtained an exclusive worldwide license to develop and commercialize darinaparsin from ZIOPHARM Oncology Inc. and has been conducting Phase II Pan-Asian study with the intended indication as treatment of relapsed and refractory PTCL[14][15].
Products[edit]
HB Human BioScience began by licensing and distributing pharmaceutical products into Colombia. Currently, apart from licensing medicines it also has its own In-House Research and Development team developing and manufacturing its own pharmaeceuticals. As of 2018, the company owns the Marketing Authorizations of over 32 medications and 2 medical devices.
Social Iniciatives and Interinstitutional Relationships[edit]
In 2015, HB Human BioScience signed an interinstitutional agreement with the National University of Colombia Science Faculty, in order to allow students to apply for an internship in the company, developing business practices.[16]
The company is affiliated with the Colombia-India Chamber of Commerce and Industry.[17]
References[edit]
- ↑ "HB Human BioScience. Innovation and Technology". www.hbhumanbioscience.com. Retrieved 2018-03-08.
- ↑ "HB HUMAN BIOSCIENCE SAS - Las Empresas". Las Empresas (in español). 2014-12-18. Retrieved 2018-05-17.
- ↑ INVIMA, COMISIÓN REVISORA DE LA SALA ESPECIALIZADA DE MEDICAMENTOS Y PRODUCTOS BIOLÓGICOS (2016). "Acta Nro 5. SALA ESPECIALIZADA DE MEDICAMENTOS Y PRODUCTOS BIOLÓGICOS" (PDF). Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Retrieved March 3, 2018.
- ↑ Gestión, Redacción (2015-08-14). "Aniversario de empresas". Gestion (in español). Retrieved 2018-03-08.
- ↑ "HB Human BioScience S.A.C." (PDF). La cámara. La revista de la CCL: 43. October 2017.
- ↑ "南方国际医药技术转移与投资平台". bio-south.org. Retrieved 2018-09-27.
- ↑ "Otro fármaco con el que tumbaron a los colombianos | ELESPECTADOR.COM". ELESPECTADOR.COM (in español). 2014-01-24. Retrieved 2018-05-17.
- ↑ "Carta de la Embajada de los Estados Unidos de América al Ministro de Salud y Protección Social, Alejandro Gaviria Uribe" (PDF). Ministerio de Salud y Protección Social. Retrieved 27 Sep 2018.
- ↑ "Requerimiento Embajador de la india 2013" (PDF). Ministerio de Salud y Protección Social [CO]. Retrieved May 17, 2018.
- ↑ "Los 864 medicamentos con precios rebajados - Las2orillas". Las2orillas (in español). 2014-04-10. Retrieved 2018-11-23.
- ↑ Salud, Opinion y (2017-06-06). "Nueva lista de 148 medicamentos en control de precio por Minsalud". Opinión y Salud (in español). Retrieved 2018-05-17.
- ↑ "Interview: Oscar Fernando Otalora Gomez - Executive Director, HB Human Bioscience, Colombia". pharmaboardroom.com. Retrieved 2018-03-08.
- ↑ "Solasia Licenses PTCL Treatment to Columbia Firm in Latin America - Pharma Japan". pj.jiho.jp. Retrieved 2018-09-27.
- ↑ "Terms of Service Violation". www.bloomberg.com. Retrieved 2018-09-27.
- ↑ "News List | Solasia Pharma K.K." Solasia Pharma K.K. Retrieved 2018-09-27.
- ↑ Facultad de Ciencias, Universidad Nacional de Colombia. "CONVENIO DE APOYO INTERINSTITUCIONAL PARA EL DESARROLLO DE PRACTICAS UNIVERSITARIAS ENTRE LA FACULTAD DE CIENCIAS DE LA UNIVERSIDAD NACIONAL DE COLOMBIA Y HB HUMAN BIOSCIENCE S A S" (PDF). Universidad Nacional de Colombia. Retrieved March 7, 2018.
- ↑ "Afiliados | Cámara Colombia India de Comercio e Industria". www.camaracoin.org (in español). Retrieved 2018-05-17.
External links[edit]
This article "HB Human BioScience" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:HB Human BioScience. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
